WeTrials
Completed

A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-FInding Study of Elismetrep (K-304) in the Treatment of Acute Migraine

What is this study?

This study tests a new medication called elismetrep to see if it safely and effectively treats sudden, severe migraine headaches. Researchers want to find the best dose to help relieve migraine pain and symptoms like nausea and sensitivity to light.

Who can participate?

Adults between 18 and 70 years old who have suffered from migraines for over a year and experience regular moderate to severe attacks may be eligible. You must have between 2 and 10 migraine attacks per month to join.

What will happen?

Participants receive either the study medication in one of four different doses or a placebo, which looks like medicine but has no active ingredients. Doctors will then compare the results to see how well the treatment works and check for safety.

Where and when?

This study has already been completed and took place at various medical centers in locations such as Alabama and Arizona. Although this specific trial is finished, its findings help pave the way for future migraine treatments.

Key Points
  • 1Testing elismetrep as a new treatment for acute migraine attacks
  • 2Comparing four different medication doses against a placebo
  • 3Study has been completed at multiple research locations

Related video

Institute for Headache and Brain Health: neurologist explains this study's results (June 2026)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Migraine

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.